Nitto Denko Corporation (Headquarters: Osaka; President, CEO & COO: Hideo Takasaki; “Nitto”, hereafter) and aceRNA Technologies Co., Ltd. (Headquarters: Kyoto; President, Teruo Susumu; "aceRNA", hereafter) announced today that they have entered into an agreement to jointly develop Switch mRNA therapy, with Nitto investing an undisclosed sum in aceRNA.
For any inquiries about this press release.
Nitto is present in 14 countries in the EMEA region. Find your local contact details here.